Nuclear unphosphorylated STAT3 correlates with a worse prognosis in human glioblastoma
- 1 June 2016
- journal article
- research article
- Published by Elsevier in Pathology - Research and Practice
- Vol. 212 (6) , 517-523
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Nonsurgical Treatment of Recurrent GlioblastomaCurrent Oncology, 2015
- Transcription Factor STAT3 as a Novel Molecular Target for Cancer PreventionCancers, 2014
- Mechanisms of Unphosphorylated STAT3 Transcription Factor Binding to DNAJournal of Biological Chemistry, 2012
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trialThe Lancet Oncology, 2009
- Histopathologic predictors of pilocytic astrocytoma event-free survivalActa Neuropathologica, 2009
- Malignant Astrocytomas Originate from Neural Stem/Progenitor Cells in a Somatic Tumor Suppressor Mouse ModelCancer Cell, 2009
- The 2007 WHO Classification of Tumours of the Central Nervous SystemActa Neuropathologica, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- STATs in oncogenesisOncogene, 2000
- Maximal activation of transcription by statl and stat3 requires both tyrosine and serine phosphorylationCell, 1995